Molecular Pharmacology, Vol 19, 109-116, Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics

Novel S49 Lymphoma Variants with Aberrant Cyclic AMP Metabolism

¹ Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, and the Cardiovascular Research Institute, University of California at San Francisco, San Francisco, California 94143

S49 mouse lymphoma cells resistant to killing by cholera toxin (but sensitive to N⁶,O²'-dibutyryl adenosine-3',5'-monophosphate) can be selected in a single step. The transition from cholera toxin sensitivity to resistance is stochastic and occurs at a rate of 1.1 x 10^-5 per cell per generation. Chemical mutagens increase the frequency of cholera toxin resistance. Screening of independently selected cholera toxin-resistant clones led to discovery of three novel variant phenotypes. Lesions in two of these phenotypes affect the guanine nucleotide regulatory component, called N, of adenylate cyclase (EC 4.6.1.1). We assessed the N protein in the variants by measuring the ability of membrane extracts to complement N-deficient S49 cyc^- membranes in vitro, and by radiolabeling peptide subunits of N in the presence of cholera toxin and [³²P]NAD⁺. Membranes of one variant phenotype, termed N^par, contain about 20% of the N activity seen in wild-type (parental) S49 membranes and show reduced radiolabeling catalyzed by cholera toxin. N^par membrane extracts partially inhibit wild-type extracts in complementing adenylate cyclase of cyc^- membranes. A second phenotype exhibits cholera toxin-specific radiolabeling of N subunits comparable to that seen in wild type, but its N protein exhibits very little activity in complementing the defect of cyc^-. Resistance to cholera toxin in the third phenotype is associated with normal N and adenylate cyclase activities, but extracts of these cells degrade adenosine 3',5'-monophosphate at a rate 4 times faster than wild-type.

Note:
ACKNOWLEDGMENTS We thank Harvey R. Kaslow, Zvi Farfel, Virginia M. Brothers, Mark MacInnes, Ted van Daalen Wetters, and Philip Coffino for useful advice and discussions.

This article has been cited by other articles:

				M. Azzi, P. G. Charest, S. Angers, G. Rousseau, T. Kohout, M. Bouvier, and G. Pineyro {beta}-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors PNAS, September 30, 2003; 100(20): 11406 - 11411. [Abstract] [Full Text] [PDF]

				A. N. Abell, D. J. McCormick, and D. L. Segaloff Certain Activating Mutations within Helix 6 of the Human Luteinizing Hormone Receptor May Be Explained by Alterations That Allow Transmembrane Regions to Activate Gs Mol. Endocrinol., December 1, 1998; 12(12): 1857 - 1869. [Abstract] [Full Text]

				D. M. Apanovitch, T. Iiri, T. Karasawa, H. R. Bourne, and H. G. Dohlman Second Site Suppressor Mutations of a GTPase-deficient G-Protein alpha -Subunit. SELECTIVE INHIBITION OF Gbeta gamma -MEDIATED SIGNALING J. Biol. Chem., October 30, 1998; 273(44): 28597 - 28602. [Abstract] [Full Text] [PDF]

				D. R. Warner, P. V. Gejman, R. M. Collins, and L. S. Weinstein A Novel Mutation Adjacent to the Switch III Domain of Gs{alpha} in a Patient with Pseudohypoparathyroidism Mol. Endocrinol., October 1, 1997; 11(11): 1718 - 1727. [Abstract] [Full Text]

				A. N. Abell and D. L. Segaloff Evidence for the Direct Involvement of Transmembrane Region 6 of the Lutropin/Choriogonadotropin Receptor in Activating Gs J. Biol. Chem., June 6, 1997; 272(23): 14586 - 14591. [Abstract] [Full Text] [PDF]

				J Kurjan, J P Hirsch, and C Dietzel Mutations in the guanine nucleotide-binding domains of a yeast G alpha protein confer a constitutive or uninducible state to the pheromone response pathway. Genes & Dev., March 1, 1991; 5(3): 475 - 483. [Abstract] [PDF]